Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase‐3, randomized, placebo‐controlled trial

BACKGROUND: Few clinical trials have evaluated long‐term treatment of nail psoriasis with biologics. OBJECTIVE: Safety and efficacy of adalimumab [ADA; Humira AbbVie Inc, North Chicago, IL, USA)] long‐term treatment (52 weeks) was evaluated in a phase‐3, randomized trial in patients with moderate‐to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Eur Acad Dermatol Venereol
Main Authors: Elewski, B.E., Baker, C.S., Crowley, J.J., Poulin, Y., Okun, M.M., Calimlim, B., Geng, Z., Reyes Servin, O., Rich, P.A.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Nails
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6899987/
https://ncbi.nlm.nih.gov/pubmed/31304993
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.15793
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados